“Find some tumor-specific receptors and attach the ligands to the nanotubes.”
As is the case with other attempts at molecular targetting, they’re apparently seeing residual uptake where they’d prefer not to. For this method to be effective they’ll need to develop a targetting and delivery system flexible enough to account for the wide disparities between one cancer and another.
The researchers are getting closer to those questions. Some drugs already target specific cancer proteins for very specific cancers. Some of these antibodies (protein receptor) are being combined with Radioactive elements to pinpoint radiation. More of these drugs are in the pipelines in Phase 2 and 3 trials.
We have been able to cure cancer in mice for 30 years.